Latest Breaking News On - Head of biotechnology research at maxim group - Page 1 : comparemela.com

Panel Session Title: Alzheimer Disease Panel Date and Time:  Wednesday May 26th, 11:00 a.m. Eastern time (8:00 a.m. Pacific time) Presented by: Maxim Group LLC | Hosted by: M-Vest Moderated by: Dr. Jason McCarthy About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and Treatment Resistant Depression (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. IN

David mossJason mccarthyInmune bioAnnovis bioChuck padalaGlobe newswire inmune bio incBiotechnology equity researchInmune bio incCompany current reports on formHead of biotechnology research at maxim groupCompany quarterly reports on formExchange commissionPanel session titleCompany annual report on formMaxim groupAlzheimer disease panel